menu search

SDGR / Schrodinger, Inc. (SDGR) CEO Ramy Farid on Q2 2022 Results - Earnings Call Transcript

Schrodinger, Inc. (SDGR) CEO Ramy Farid on Q2 2022 Results - Earnings Call Transcript
Schrodinger, Inc. (NASDAQ:SDGR ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Jaren Madden - SVP, IR & Corporate Communications Ramy Farid - CEO, President & Director Jenny Herman - SVP, Finance & Corporate Controller Karen Akinsanya - President, Research & Development Therapeutics Conference Call Participants Michael Ryskin - Bank of America Merrill Lynch Gary Nachman - BMO Capital Markets Vikram Purohit - Morgan Stanley Operator Thank you for standing by. Welcome to Schrödinger's conference call to review second quarter 2022 financial results. Read More
Posted: Aug 4 2022, 20:31
Author Name: Seeking Alpha
Views: 103111

SDGR News  

Schrödinger, Inc. (SDGR) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 1, 2023

Schrödinger, Inc. (SDGR) Q3 2023 Earnings Call Transcript

Schrödinger, Inc. (NASDAQ:SDGR ) Q3 2023 Results Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Jaren Madden - Senior Vice more_horizontal

Schrodinger: Leading The AI Healthcare Revolution

By Seeking Alpha
September 29, 2023

Schrodinger: Leading The AI Healthcare Revolution

Schrödinger is a leading AI drug discovery company with a comprehensive platform used by researchers and scientists worldwide. The company's flagship more_horizontal

Schrodinger: More Than An AI Bubble Stock

By Seeking Alpha
September 2, 2023

Schrodinger: More Than An AI Bubble Stock

Schrodinger's stock has performed well this year due to AI hype and strength in its drug discovery business. While the company appears attractively va more_horizontal

Why Shares of Schrödinger Are Falling Thursday

By The Motley Fool
August 3, 2023

Why Shares of Schrödinger Are Falling Thursday

Second-quarter revenue was down 9% year over year. Schrödinger increased revenue guidance for software revenue but decreased it for drug discovery. more_horizontal

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Misses Revenue Estimates

By Zacks Investment Research
August 2, 2023

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Misses Revenue Estimates

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to lo more_horizontal

Why These 3 Stocks Are the Best Ways to Play AI Right Now

By InvestorPlace
July 11, 2023

Why These 3 Stocks Are the Best Ways to Play AI Right Now

Goldman Sachs recently asserted “that AI adoption could boost productivity growth by 1.5 percentage points per year over a 10-year period.” Th more_horizontal

Schrodinger, Inc. (SDGR) Surges 6.6%: Is This an Indication of Further Gains?

By Zacks Investment Research
June 14, 2023

Schrodinger, Inc. (SDGR) Surges 6.6%: Is This an Indication of Further Gains?

Schrodinger, Inc. (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate more_horizontal

3 Pharma Stocks That Will Boom Thanks to AI

By InvestorPlace
May 26, 2023

3 Pharma Stocks That Will Boom Thanks to AI

A Deloitte report about artificial intelligence (AI) in the life sciences puts it bluntly. Big data is the new currency for biopharma firms. more_horizontal


Search within

Pages Search Results: